This article has been disseminated on behalf of Quantum BioPharma Ltd.ย and may include paid advertising.ย
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) was the focus of CTV Newsโ W5 program, which aired Part Three of its investigative series examining the companyโs allegations of stock spoofing tied to its USD $700 million lawsuit against CIBC and RBC. The episodes detail rising market-manipulation cases in Canada and highlight Quantumโs call for accountability, with CEO Zeeshan Saeed reaffirming the companyโs commitment to defending shareholders and advancing MS research, and Co-Executive Chair Anthony Durkacz offering up to USD $7 million for information leading to a final judgment or settlement in related litigation.
To view the full press release, visitโฏhttps://ibn.fm/OsuC0
About Quantum BioPharma Ltd.
Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (โ Lucid โ), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd(TM) and spun out its OTC version to a company, Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans. Quantum BioPharma retains ownership of 20.11% (as of March 31, 2025) of Unbuzzd Wellness Inc. The agreement with Unbuzzd Wellness Inc. also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
NOTE TO INVESTORS:โฏThe latest news and updates relating to QNTM are available in the companyโs newsroom atโฏhttps://ibn.fm/QNTM
About InvestorWire
InvestorWireย (โIWโ) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands withinย theย Dynamic Brand Portfolioย @ย IBNย that delivers:ย (1) access to a vast network of wire solutions viaย InvestorWireย to efficiently and effectively reach a myriad of target markets, demographics and diverse industries;ย (2) article andย editorial syndication to 5,000+ outlets;ย (3) enhancedย press release enhancementย to ensure maximum impact;ย (4)ย social media distributionย via IBN to millions of social media followers;ย and (5) a full array of tailoredย corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in todayโs market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visitย https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published:ย https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com
InvestorWire is powered byย IBN
